Periodic treatment with autologous erythrocytes loaded with dexamethasone 21-phosphate for fistulizing pediatric Crohn's disease: Case report

Journal of Pediatric Gastroenterology and Nutrition

Volumn 42, Issue 3, 2006, Pages 313-315

  Castro, Massimo ^a   Knafelz, Daniela ^a   Rossi, Luigia ^b   Ambrosini, Maria Irene ^a   Papadatou, Bronislava ^a   Mambrini, Giovanni ^c   Magnani, Mauro ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

^c DIDECO SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BUDESONIDE; DEXAMETHASONE SODIUM PHOSPHATE; INFLIXIMAB; MESALAZINE; METRONIDAZOLE; PREDNISOLONE;

ABDOMINAL ABSCESS; ANAPHYLAXIS; ARTICLE; CASE REPORT; COLON BIOPSY; COLON CROHN DISEASE; COLON ULCER; COLONOSCOPY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENTEROCUTANEOUS FISTULA; ERYTHROCYTE; FEMALE; HUMAN; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; ULTRASOUND;

ADOLESCENT; CAPSULES; CHILD; CROHN DISEASE; DEXAMETHASONE; DRUG CARRIERS; ERYTHROCYTES; FEMALE; HUMANS; INTESTINAL FISTULA; SAFETY; TREATMENT OUTCOME;

FISTULA;

EID: 33645313485     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000188006.59128.47     Document Type: Article

References (15)

1. Banerjee S, Peppercorn MA. Inflammatory bowel disease. Medical therapy of specific clinical presentations. Gastroenterol Clin North Am 2002;31:185-202.
2. Faubion WA, Jr, Loftus EV, Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60.
3. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
4. Schimmer BP, Parker KL. Adrenocorticotropic hormone. In: The Pharmacological Basis of Therapeutics, ed 9. New York: McGraw-Hill, 1996, pp. 1458-85.
5. Escher JC, Taminiau JA, Nieuwenhuis EE, Buller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 2003;9:34-58.
6. Warman JI, Korelitz BI, Fleisher MR, Janardhanam R. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003;37:220-5.
7. Markowitz JF. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease. Rev Gastroenterol Disord 2003;1(Suppl 3):S23-9.
8. Diamanti A, Papadatou B, Knafelz D, Gambarara M, Ferretti F, Castro M. Clinical outcome and safety of periodic infliximab therapy in children and adolescents with Crohn's disease. J Pediatr Gastroenterol Nutr 2004;39:302-3.
9. Diamanti A, Papadatou B, Knafelz D, Gambarara M, Ferretti F, Castro M. Complications of infliximab therapy in children and adolescents affected by Crohn's disease. Am J Gastroenterol 2003;98:2812-3.
10. Lamireau T, Cezard JP, Dabadie A, et al. French-Speaking Group for Pediatric Gastroenterology Nutrition. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004;10:745-50.
11. Rossi L, Serafini S, Cenerini L, et al. Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease. Biotechnol Appl Biochem 2001;33:85-9.
12. Magnani M, Rossi L, Fraternale A, et al. Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther 2002;9:749-51.
13. Magnani M, Rossi L, D'ascenzo M, Panzani I, Bigi L, Zanella A. Erythrocyte engineering for drug delivery and targeting. Biotechnol Appl Biochem 1998;28:1-6.
14. Rossi L, Castro M, D'Orio F, et al. Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. Blood Cells Mol Dis 2004;33:57-63.
15. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.